Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.68
CLVS's Cash to Debt is ranked higher than
58% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CLVS: 1.68 )
CLVS' s 10-Year Cash to Debt Range
Min: 1.68   Max: No Debt
Current: 1.68

Equity to Asset 0.42
CLVS's Equity to Asset is ranked higher than
57% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLVS: 0.42 )
CLVS' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.42
Current: 0.42

F-Score: 4
Z-Score: 3.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1163.00
CLVS's Operating margin (%) is ranked higher than
56% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CLVS: -1163.00 )
CLVS' s 10-Year Operating margin (%) Range
Min: -1163   Max: -1163
Current: -1163

Net-margin (%) -1174.54
CLVS's Net-margin (%) is ranked higher than
55% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CLVS: -1174.54 )
CLVS' s 10-Year Net-margin (%) Range
Min: -1174.54   Max: -1174.54
Current: -1174.54

ROE (%) -37.53
CLVS's ROE (%) is ranked higher than
69% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CLVS: -37.53 )
CLVS' s 10-Year ROE (%) Range
Min: -144.26   Max: -26.78
Current: -37.53

-144.26
-26.78
ROA (%) -22.89
CLVS's ROA (%) is ranked higher than
73% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CLVS: -22.89 )
CLVS' s 10-Year ROA (%) Range
Min: -65.51   Max: -21.25
Current: -22.89

-65.51
-21.25
ROC (Joel Greenblatt) (%) -8872.28
CLVS's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CLVS: -8872.28 )
CLVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8628.31   Max: -4951.81
Current: -8872.28

-8628.31
-4951.81
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CLVS Guru Trades in Q4 2013

Steven Cohen 1,166,700 sh (+7.30%)
Jim Simons Sold Out
» More
Q1 2014

CLVS Guru Trades in Q1 2014

Steven Cohen 458,238 sh (-60.72%)
» More
Q3 2014

CLVS Guru Trades in Q3 2014

Jim Simons 22,000 sh (New)
» More
Q4 2014

CLVS Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.80
CLVS's P/B is ranked higher than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CLVS: 9.80 )
CLVS' s 10-Year P/B Range
Min: 2.83   Max: 9.8
Current: 9.8

2.83
9.8
P/S 228.90
CLVS's P/S is ranked lower than
59% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CLVS: 228.90 )
CLVS' s 10-Year P/S Range
Min: 92   Max: 229
Current: 228.9

92
229
Current Ratio 10.28
CLVS's Current Ratio is ranked higher than
88% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CLVS: 10.28 )
CLVS' s 10-Year Current Ratio Range
Min: 4.73   Max: 15.68
Current: 10.28

4.73
15.68
Quick Ratio 10.28
CLVS's Quick Ratio is ranked higher than
88% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CLVS: 10.28 )
CLVS' s 10-Year Quick Ratio Range
Min: 4.73   Max: 15.68
Current: 10.28

4.73
15.68
Days Sales Outstanding 176.51
CLVS's Days Sales Outstanding is ranked higher than
70% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CLVS: 176.51 )
CLVS' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 176.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 110.90
CLVS's Price/Net Cash is ranked higher than
55% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. CLVS: 110.90 )
CLVS' s 10-Year Price/Net Cash Range
Min: 2.45   Max: 67.47
Current: 110.9

2.45
67.47
Price/Net Current Asset Value 110.90
CLVS's Price/Net Current Asset Value is ranked higher than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. CLVS: 110.90 )
CLVS' s 10-Year Price/Net Current Asset Value Range
Min: 2.43   Max: 51.85
Current: 110.9

2.43
51.85
Price/Tangible Book 59.40
CLVS's Price/Tangible Book is ranked lower than
63% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. CLVS: 59.40 )
CLVS' s 10-Year Price/Tangible Book Range
Min: 2.39   Max: 15.53
Current: 59.4

2.39
15.53
Price/Median PS Value 1.70
CLVS's Price/Median PS Value is ranked higher than
75% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CLVS: 1.70 )
CLVS' s 10-Year Price/Median PS Value Range
Min: 1.02   Max: 1.02
Current: 1.7

Earnings Yield (Greenblatt) -6.20
CLVS's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CLVS: -6.20 )
CLVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -7.7   Max: 0
Current: -6.2

-7.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 
comment on CLVS Mar 06 2013 


More From Other Websites
Nasdaq stocks posting largest percentage increases Apr 24 2015
Clovis Oncology to Announce First Quarter 2015 Financial Results and Host Webcast Conference Call on... Apr 23 2015
Clovis Oncology to Announce First Quarter 2015 Financial Results and Host Webcast Conference Call on... Apr 23 2015
Clovis Deal Chatter Heats Up Again as Goldman Says Buy: Real M&A Apr 22 2015
Clovis Oncology (CLVS) Falls: Stock Goes Down 5.3% - Tale of the Tape Apr 20 2015
Microsoft Corporation (MSFT), Valeant Pharmaceuticals Intl Inc (VRX): Partner Fund Management’s... Apr 18 2015
AstraZeneca lung cancer drug delays disease by more than a year Apr 17 2015
Clovis Oncology (CLVS) in Focus: Stock Rises 7.5% - Tale of the Tape Apr 16 2015
Clovis Technology Gets Big Boost From Goldman Upgrade Apr 13 2015
Street Talk: CLVS under the radar Apr 13 2015
Netflix leads S&P 500 gainers on upgrade Apr 13 2015
Clovis Oncology (CLVS) Stock Spikes Today on Analyst Upgrade Apr 13 2015
Top Analyst Upgrades and Downgrades: Apple, BP, Hewlett-Packard, Philip Morris, UnitedHealth, AT&T... Apr 13 2015
Goldman Just Raised Its Clovis Oncology Target ~50%, Upgrades To Buy Apr 13 2015
Clovis Oncology (CLVS) in Focus: Stock Moves 8% Higher - Tale of the Tape Apr 08 2015
Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog Apr 07 2015
Clovis Cancer 'Breakthrough,' Oculus Flop Top Biotech News Late Apr 06 2015
Viacom shares slip after hours on reorganzation Apr 06 2015
After-hours buzz: A Schulman, Viacom, Clovis & more Apr 06 2015
Clovis gets breakthrough status for ovarian cancer drug Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK